Dose Predictions for Drug Design

Abstract

The efficacious dose of a drug is perhaps the most holistic metric reflecting its therapeutic potential. Dose is predicted at many stages in drug discovery and development. Prior to the 1990s, dose prediction was limited to the drug “working” at a reasonable dose and dose regimen in an animal model. Through the early 2000s, dose predictions were generated at candidate nomination and then refined during clinical development. Currently, dose predictions can be made early in drug discovery to enable drug design. Dose predictions at this stage can identify critical drug properties for a viable dose regimen and provide clinically relevant context to lead optimization. In this paper, we give an overview of the opportunities and challenges associated with dose prediction for drug design. A number of general considerations, approaches, and case examples are discussed.

There is Only One Valid Definition of Clearance: Critical Examination of Clearance Concepts Reveals the Potential for Errors in Clinical Drug Dosing Decisions

“…Drug development is an extremely expensive and time-consuming process with an unacceptable and very poor success rate. Since clearance is such a critical parameter, it seems obvious that if we could predict an NME’s clearance prior to dosing the drug to humans or even animals, this could markedly speed the drug development process ( 3 , 4 ). However, even when conducting what should be relevant and translatable in vitro measures of drug elimination with human hepatocytes and microsomes, successful prediction of metabolic clearance within 2-fold of measured values fails 60–80% of the time based on numerous evaluations of IVIVE success ( 5 – 7 ) .…”

Relating Conformational Equilibria to Conformer‐Specific Lipophilicities: New Opportunities in Drug Discovery

“…In addition, the lower the dose, the lower the risk of toxicity and/or side effects stemming from non-specific off target activity. [1] Another crucial determinant of drug dosing is lipophilicity (logP), as a proxy for a host of physical parameters related to ADMET (absorption, distribution, metabolism, excretion and toxicity). [2] Optimal compound lipophilicity ranges have been proposed.…”

Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID‐19 Therapeutics

“…Of course, biological context can affect antiviral potency in ways that are independent of drug disposition (e.g., cell type, multiplicity of infection, duration of infection, and timing of treatment relative to infection). Although this aspect receives comparatively less focus, much can be learned from other therapeutic areas regarding the biological factors that affect potency between in vitro and in vivo systems 13 . Given the number of potentially confounding factors, it is of little surprise that clinically effective concentrations across a wide range of therapeutics are often not simply related to apparent in vitro measures of potency without consideration of differences in biological context between systems 14 …”